Overview
- Unique Pharmaceutical Laboratories initiated a voluntary consumer‑level recall on July 18 for four lots of cetirizine hydrochloride 5 mg bottles after a U.S. pharmacy technician noticed red dots and discoloration on tablets.
- The recall covers lots GY825029, GY825030, GY825031 and GY825032 (NDC 16571-401-10, exp. 10/2028) distributed nationwide by Rising Pharma Holdings, which is notifying customers and arranging returns.
- Company and FDA notices say the tablets may be cross‑contaminated with ranitidine and warn that people with ranitidine hypersensitivity could suffer severe reactions including anaphylaxis; no adverse events have been reported so far.
- One news outlet reported follow‑up lab tests that allegedly traced ranitidine to two lots, but that finding is not confirmed in the company or FDA recall posting and remains a developing item.
- The recall raises questions about manufacturing and supply‑chain quality control at the India‑based plant and could prompt additional testing for contaminants such as NDMA and wider regulatory scrutiny of exported generics.